Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback
Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has received feedback in response to its previously announced Type B Meeting request to the U.S. Food and Drug Administration . The purpose of the FDA meeting request was to confirm Apricus' strategy for addressing the deficiencies contained in the 2008 Complete Response letter.
from Biotech News
0 Comments